key: cord-0893691-h0m8zutb
authors: Hefferon, Kathleen
title: Plant Virus Expression Vectors: A Powerhouse for Global Health
date: 2017-07-30
journal: Biomedicines
DOI: 10.3390/biomedicines5030044
sha: e98c156b8632c84d14cfb03a1614b36563479bed
doc_id: 893691
cord_uid: h0m8zutb

Plant-made biopharmaceuticals have long been considered a promising technology for providing inexpensive and efficacious medicines for developing countries, as well as for combating pandemic infectious diseases and for use in personalized medicine. Plant virus expression vectors produce high levels of pharmaceutical proteins within a very short time period. Recently, plant viruses have been employed as nanoparticles for novel forms of cancer treatment. This review provides a glimpse into the development of plant virus expression systems both for pharmaceutical production as well as for immunotherapy.

Plant-derived biopharmaceuticals, including vaccines, monoclonal antibodies, and other therapeutic proteins, are rapidly emerging into the marketplace. Today, commercialized plant-made pharmaceutical products are offered by Protalix Bio Therapeutics, Inc. (Karmiel, Israel), Planet Biotechnology, Inc. (Hayward, CA, USA), and Icon Genetics, GmbH (Halle, Germany). Biologics derived from plants have been demonstrated to be effective, safe, and inexpensive. They are easy to generate en masse and can be stored at ambient temperatures [1] . These attributes make plant-derived biopharmaceuticals attractive alternatives for providing medicines that were previously inaccessible to poor developing countries. While this longstanding goal has yet to be realized, plant-derived vaccines and other pharmaceuticals have found additional applications. For example, plant-made vaccines can be stockpiled as a measure of protection against global pandemics or biological warfare threats, and can be used for providing personalized medicines that are both rapid in turnaround and affordable to implement [2, 3] .

The first plant-derived pharmaceuticals were generated from transgenic plants, with length of generation time and protein expression levels being two of the principal caveats of this technological approach. In response, transient expression through the use of plant virus expression vectors became an attractive venue by which biopharmaceuticals could also be generated [4] . Virus vector-based expression systems could simultaneously shorten production time and increase pharmaceutical yield, while removing concerns from the general public about the use of genetically modified organisms (GMOs). More recently, plant viruses have found a niche in the field of cancer immunotherapy, by acting as nanoparticles which can home in on and elicit a form of highly localized immune response to solid tumors. Plant virus nanoparticles can even be engineered to carry a drug payload to cancer cells, thus offering a new and potent arsenal for cancer researchers and physicians alike [5] .

With this history, the development of plant virus expression vectors for biopharmaceutical development has become a powerful tool. This review aims to describe some of the virus expression systems currently in use and explore some of their most recent applications, both as production systems and as nanoparticles for cancer immunotherapy.

Rigid rod-shaped tobamoviruses include the Tobacco mosaic virus (TMV). TMV has 2130 copies of the capsid protein (CP), and was the first virus that has been engineered as a deconstructed vector system [10, 11] . This new expression system is composed of two modules; one containing the replicase, the portion of the genome responsible for viral replication, and the other containing the site of foreign gene expression. TMV can be used to express both full length proteins and epitopes in the form of fusion proteins, and examples include Noris et al., Huang [27, 28] . As another example, TMV has undergone extensive development by Fraunhofer USA as a potential vaccine against the pandemic H1N1 influenza virus, and clinical trials are currently underway [29] [30] [31] [32] . Others have also examined the parameters of TMV-based influenza vaccine development. For example, Matsuda et al. found that temperature post viral vector inoculation influenced the spatial expression of hemagglutinin (HA) content in Nicotiana benthamiana leaves [33] . The authors determined that 20 • C is the optimal temperature required to obtain a maximal and stable yield of HA. Similarly, Patil et al. have shown that light intensity can affect the movement of viral gene products [34] .

Liu and Kearney have developed a tobamovirus that infects legumes, based on Sun Hemp Mosaic Virus (SHMV) that incorporates some of the attributes of the strategies developed by Icon and TRBO vectors [35] . Their "SHEC" vector lacks a CP, and thus cannot form virions, and also replicates very poorly in the absence of the silencing suppressor P19. Such tobamovirus-based systems can further regulate vaccine production under highly inducible and contained conditions.

The recent discovery of adjuvant properties of TMV has sparked a renewed interest in the use of this virus as a delivery vehicle for immunotherapy. TMV particles have been demonstrated to be taken up by dendritic cells and to exhibit activation properties, resulting in robust CD8+ T cell responses [36, 37] . Banik et al. used TMV particles to act as both an adjuvant and an epitope display system for vaccine development against the facultative intracellular pathogen Francisella tularensis that did not elicit adverse reactions when administered to mice, yet protected them against respiratory challenges with very high doses of F. tularensis Live Vaccine Strain LVS [38] . Similarly, Jones et al. used this virus-based delivery platform as a means to generate a malaria transmission blocking vaccine (TBV), which specifically targets proteins expressed in the mosquito midgut during Plasmodium falciparum development. TBV proteins, such as the Pfs25 protein, could be a potential target to reduce the transmission of malaria [39] . The TMV deconstructed vector has also been used to produce HPV vaccines based on the VLPs composed of the L1 protein. Such a vaccine could offer a safe and inexpensive vaccine for the poor in developing countries [40, 41] .

The MagnICON deconstructed vector is perhaps most well-known for its use in efforts to develop personalized medicine against non-Hodgkin's lymphoma (NHL) [42] . NHL is a cancer of overproliferating B cells, with an estimated 70,000 new cases in 2014 alone. Since malignant B cells present a unique cell surface idiotype that is specific to that individual, patients can be vaccinated using their own idiotype. TMV constructs composed of the scFv subunit and full-length idiotype IgG molecules were expressed in deconstructed MagnICON vectors as heavy and light chains, which assembled into full immunoglobulins in the plant [43, 44] . Each vaccine construct has successfully passed Phase I clinical trials, been demonstrated to be safe, and elicit few adverse effects. The number of patients who mounted immune responses was comparable to the results of earlier clinical trials using follicular lymphoma idiotype vaccines that have been generated using other production platforms. Furthermore, vaccine manufacture is extremely rapid, taking less than three months to obtain a completed vaccine based upon US FDA cGMP guidance from an initial biopsy [45, 46] . For further information requiring the large scale production of pharmaceutical proteins using the MagnICON system, please refer to Klimyuk et al. [47] .

The tobacco mosaic virus has been engineered to be tumor-specific using the tumor homing peptide cRGD, which has been functionalized to the surface of the virus. TMV particles that display cRGD can become rapidly internalized into tumor cells. Doxorubicin and other anti-cancer drugs can also be conjugated to TMV so that they can be taken up by cancer cells and released during endocytosis [48] .

Potato Virus X (PVX), a flexuous, rod-shaped virus containing a plus-sense RNA molecule, has also been engineered extensively as an expression vector for biopharmaceuticals. The genome of PVX consists of replicase and capsid protein genes, as well as a triple gene block, whose products are responsible for virus movement. PVX has been used to express full-length proteins, fusion proteins, epitopes that are displayed on the outer surface of the assembled virus particle, and more recently, PVX nanoparticles have been demonstrated to block tumor progression in animal models [49] . For example, a PVX-based expression system has been engineered to produce the N and M proteins of Sudden Acquired Respiratory Syndrome Coronavirus (SARS-CoV) antigens [50] . The plant-derived N protein can be used to examine the presence of N-specific antibodies in the sera of patients who had been exposed to coronavirus.

PVX has been employed for the development of a universal influenza vaccine consisting of an epitope derived from the extracellular domain of H1N1 virus matrix protein 2 (M2e). The researchers fused M2e to bacterial flagellin, a strong mucosal adjuvant, in order to improve M2e immunogenicity [51] . N. benthamiana plants infected with a PVX vector expressing this fusion protein were able to produce 1 mg/g fresh leaf tissue or 30% total soluble protein, and inoculated mice were protected from influenza infection.

PVX has produced other antigens as well. For example, Uhde-Holzem et al. (2010) used PVX to express the epitope HVR1 from the Hepatitis C virus (HCV) as a fusion protein [52] . Mice immunized parenterally elicited an IgG response, and sera from chronically infected HCV patients reacted positively to the PVX-HVR1 epitope. Similarly, Mohammadzadeh et al. fused epitopes of the HCV core antigen to Hepatitis B virus surface antigen (HBsAg), and expressed the resulting chimeric construct from the second coat protein promoter of a PVX vector [53] . The papaya mosaic potexvirus (PapMV) has been used to express an epitope of the envelope protein of HCV to generate a long lasting humoral antibody response in mice [54] . PapMV has also been employed as a carrier for a potential universal flu vaccine, by fusing an epitope of M2e to the outer surface of PapMV nanoparticles [55] .

Recently, PVX has been designed to act as a nanoparticle for tumor immunotherapy. PVX nanofilaments carrying monoclonal antibodies of herceptin (Trastuzumab) for breast cancer patients [56] could induce apoptosis in breast cancer cell lines. PVX expressing a mutant version of the HPV16 E7 oncoprotein as part of a fusion protein with lichenase protected mice from tumor growth by generating a strong cytotoxic T-cell response [57, 58] . External lysine residues on the capsid protein of PVX can be functionalized to take on conjugates. Shukla et al. (2013) found that PVX accumulated in the center of solid tumors, suggesting that PVX will be useful for tissue-specific imaging and drug delivery [59] .

PapMV also has immunostimulatory properties, and can act as a nanoparticle. PapMV nanoparticles can elicit an α-IFN-dependent response, and when administered intra-tumorally can slow down melanoma progression and prolong survival in animal models [58] [59] [60] [61] [62] . PapMV undergoes rapid endocytosis by antigen-presenting cells, resulting in CD8+ T cell proliferation. Mice treated systemically with PapMV nanoparticles followed by B16-OVA cells six hours later exhibited fewer tumor nodules compared to control mice. The fact that this result could not be reproduced with capsid monomers or naked virus RNA indicated that the assembled nanoparticle itself was required for immune protection [60] .

The Comovirus Cowpea mosaic virus (CPMV) has undergone extensive development as an expression vector. CPMV is an icosahedral virus of 30 nm in diameter, comprised of 60 large (L) and 60 small (S) capsid proteins. The genome of CPMV is bipartite, with RNA-2 being the principal component of expression vector development. CPMV has been utilized extensively in antigenic presentation and full-length protein expression as part of a fusion protein that can undergo proteolytic cleavage to release the therapeutic protein, as well as in material science research, such as the formation of magnetic clusters and biosensors [63] [64] [65] [66] . For example, Medicago, Inc. (Durham, NC, USA) has used the CPMV vector to generate virus-like particles (VLPs) carrying influenza virus HA antigens [67] . These VLPs protect against lethal viral challenge in animal models, and are now undergoing a Phase 2 clinical trial with over 250 volunteers. Medicago's CPMV production system enables a vaccine to be generated within 3 weeks of the release of the influenza strain sequence information, with an easily adaptable upscaling capacity.

The CPMV deconstructed vector system pEAQ involves the expression of foreign proteins without the need for viral replication [68, 69] , thus relieving the cell from any hindrance created from viral cycle progression that negatively impacts protein accumulation. This involves the positioning of the foreign gene between the 5 leader sequence and 3 untranslated region (UTR) of RNA-2, as well as the deletion of an in-frame initiation codon found upstream of the main translation initiation site of RNA-2. The resulting vector provides for a substantial increase in foreign protein production.

A new vector, known as pCPMV-HT (Cowpea Mosaic Virus Hyper-Trans expression system) has been engineered that also provides high translational efficiency [70, 71] . These vectors have been used to generate vaccines against the bluetongue virus, HIV, Dengue, and the influenza virus [72, 73] .

CPMV particles have also been found to bind to vimentin displayed on the surface of HeLa cells, and are able to be taken up by endocytosis [74] [75] [76] . The fact that CPMV can be internalized by antigen-presenting cells enables it to prime the antibody response. CPMV nanoparticles have thus been shown to directly stimulate the immune system to combat various cancers. CPMV capsid proteins can be driven to self-assemble in the absence of RNA to form empty non-infectious virus-like particles (eVLPs), which can in turn be directly applied to a tumor and alter the surrounding microenvironment to potentiate tumor immunity through the activation of quiescent neutrophils in the neighboring region. Since the immune response is highly localized, patient adverse responses are minimalized [76] . For example, Lizotte et al. used mouse models to demonstrate that CPMV nanoparticles could act as effective immunotherapies for lung melanoma and other cancers, and were capable of inducing innate immune cell-mediated anti-tumor responses [77] . The authors were also able to increase proinflammatory cytokine levels by providing CPMV nanoparticles to bone marrow cell cultures. A weekly injection with CPMV nanoparticles further reduced tumor burden in colon tumors as well as in ovarian and breast cancers. In the future, CPMV could carry anticancer drugs as a payload to improve its ability to reduce tumors.

The Cowpea mosaic virus expression vector pEAG-HT has also been used to express the extracellular domain of the rat ErbB2 in tobacco plants [78] . ErbB2 is an epidermal growth factor-related protein, and its aberrant expression can lead to a variety of cancers. Plant extracts expressing ErbB2 that were injected into mice elicited immune responses and potent antitumour activity.

One possible direction of vector development may include the merging of genetic elements from two vastly different virus expression systems. This next section describes two such systems.

In the first example, Mardanova et al. utilized an expression vector construct based on PVX, along with a translational enhancer from RNA 4 of the alfalfa mosaic virus (AMV), and combined it with the CPMV-based pEAQ-HT vector backbone driving a suppressor of gene silencing to create a new vector expression system (pEff) [79] . pEff is smaller in size and has been used to express a candidate influenza vaccine protein m2e fused to HBc in the form of virus-like particles to levels several times higher than those either PVX or the CPMV-based vector system has produced alone.

In the second example, TMV has been used to express the genome of the Alphavirus Flock house virus (FHV), a small insect virus that can replicate to high levels in plants without inducing apoptosis. By including origins of assembly (ori) from TMV into the Flock house virus genome, a pseudovirus consisting of the FHV genome encapsidated by TMV coat protein was generated. Since TMV behaves like an adjuvant and can stimulate an immune response, this pseudovirus approach can be used to produce novel vaccines from plants [80] .

Geminiviruses, with their twinned capsid morphology, are single-stranded circular DNA viruses, and are capable of undergoing replication in a broad range of host plants at a high copy number. As a result, geminiviruses are suitable to develop as expression vectors [81] . The geminivirus Bean yellow dwarf virus (BeYMV) has been engineered to produce efficacious monoclonal antibodies to the Ebola, Zika, and West Nile viruses, respectively [82] . Edward Rybicki's group in South Africa has utilized BeYDV to express constructs containing HPV L1 and L2 capsid proteins along with a secreted embryonic alkaline phosphatase (SEAP) reporter construct to assemble into the encapsidated HPV pseudovirions (PsV) in tobacco plants [83, 84] .

A geminivirus vector based on the Beet Curly top virus (BCTV) has been used to generate a vaccine against hepatitis A [85] . As another example, the dual-module in-plant activation (INPACT) expression platform was developed in tobacco yellow dwarf virus (TYDV) to control foreign gene expression [86, 87] . By interrupting an expression cassette by a plant intron, the protein of interest is expressed only after post-transcriptional processing, thus offering further control of expression of the gene of interest.

Fundamental difficulties remain for populations of remote, impoverished regions to access vaccines and other biopharmaceutical protein, including high cost and limited accessibility. This prevents many from achieving better health, and as a result better livelihoods for themselves and their families. Plant-made vaccines could slow the spread of infectious diseases that are major killers, such as HIV, HBV, and malaria. Plants possess other advantages as expression systems; they do not harbor mammalian pathogens and in certain instances can undergo similar post-translational modifications to their mammalian counterparts. Pharmaceuticals derived from plants can easily be purified, or in specific cases merely partially purified prior to oral administration.

Plant-made biopharmaceuticals to fight cancer are increasing in number. Plant-made vaccines which combat oncogenic viruses that are of concern to resource poor countries, such as Hepatitis B, Hepatitis C, and Human papillomavirus, are under development and could make a huge impact on the quality of life for hundreds of millions of people. The generation of monoclonal antibodies to combat cancer in a variety of plants could also assist developing countries. The recent discovery of plant virus nanoparticles to target and penetrate solid tumors is particularly interesting [88] [89] [90] [91] . Plant virus nanoparticles with drugs functionalized to their surfaces would be efficacious, low in cost, easy to produce en masse, and low in toxicity, which are ideal qualities for a resource-poor setting.

Plant virus particles can also be a platform technology for developing nations to utilize for growing their own pharmaceutical industries. By equipping poor countries with virus constructs and freedom to operate, a plant-made pharmaceutical industry could become a reality. Improvements in manufacturing infrastructure, financial support, and the maturation of a regulatory framework surrounding plant-derived pharmaceuticals are all essential for their commercialization in the developing world. If these obstacles are overcome, it would seem that many of the examples presented in this review could play a significant role in improving the lives of many. 

Clinical development of plant-produced recombinant pharmaceuticals: Vaccines, antibodies and beyond

Plant virus expression vectors set the stage as production platforms for biopharmaceutical proteins

Current status of viral expression systems in plants and perspectives for oral vaccines development

Transient production of recombinant pharmaceutical proteins in plants: evolution and perspectives

Cancer immunotherapy: A vaccine from plant virus proteins

Viral vectors for the expression of proteins in plants

High-efficiency protein expression in plants from agroinfection-compatible Tobacco mosaic virus expression vectors

TRBO: A high-efficiency tobacco mosaic virus RNA-based overexpression vector

A plant-produced H1N1 trimeric hemagglutinin protects mice from a lethal influenza virus challenge

Safety and immunogenicity of a plant-produced recombinantmonomer hemagglutinin-based influenza vaccine derived frominfluenza A (H1N1)pdm09 virus: A Phase 1 dose-escalation study in healthy adults

Functional testing of an inhalable nanoparticle based influenza vaccine using a human precision cut lung slice technique

Plants as an innovative and accelerated vaccine-manufacturing solution

Effect of temperature post viral vector inoculation on the amount of hemagglutinin transiently expressed in Nicotiana. benthamiana leaves

Light intensity and temperature affect systemic spread of silencing signal in transient agroinfiltration studies

A tobamovirus expression vector for agroinfection of legumes and Nicotiana

Tobacco mosaic virus efficiently targets DC uptake, activation and antigen-specific T cell responses in vivo

Humans have antibodies against a plant virus: Evidence from tobacco mosaic virus

Development of a Multivalent Subunit Vaccine against Tularemia Using Tobacco Mosaic Virus (TMV) Based Delivery System

A novel plant-produced Pfs25 fusion subunit vaccine induces long-lasting transmission blocking antibody responses

Engineering and expression of a RhoA peptide against respiratory syncytial virus infection in plants

Scalable Production of HPV16 L1 Protein and VLPs from Tobacco Leaves

Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study

Tobacco derived cancer vaccines for non-Hodgkin's lymphoma: Perspectives and progress

Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma

Safety of plant-made pharmaceuticals: Product development and regulatory considerations based on case studies of two autologous human cancer vaccines

Clinical Safety and Immunogenicity of Tumor-Targeted, Plant-Made Id-KLH Conjugate Vaccines for Follicular Lymphoma

Production of Recombinant Antigens and Antibodies in Nicotiana benthamiana Using "Magnifection" Technology: GMP-Compliant Facilities for Small-and Large-Scale Manufacturing

Tobacco mosaic virus-based protein nanoparticles and nanorods for chemotherapy delivery targeting breast cancer

To target or not to target: Active vs. passive tumor homing of filamentous nanoparticles based on potato virus X

Antigen Production in Plant to Tackle Infectious Diseases Flare Up: The Case of SARS. Front

Rapid high-yield expression of a candidate influenza vaccine based on the ectodomain of M2 protein linked to flagellin in plants using viral vectors

Immunogenic properties of chimeric potato virus X particles displaying the hepatitis C virus hypervariable region I peptide R9

Co-expression of hepatitis C virus polytope-HBsAg and p19-silencing suppressor protein in tobacco leaves

Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: Evidence for the critical function of multimerization

Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform

A new application of plant virus nanoparticles as drug delivery in breast cancer

Expression of Human papillomavirus 16 E7ggg oncoprotein on N-and C-terminus of Potato virus X coat protein in bacterial and plant cells

Immunotherapy of HPV-associated cancer: DNA/plant-derived vaccines and new orthotopic mouse models

The Two-Faced Potato Virus X: From Plant Pathogen to Smart Nanoparticle

Potentiating Cancer Immunotherapy Using Papaya Mosaic Virus-Derived Nanoparticles

Novel plant virus-based vaccine induces protective cytotoxic T-lymphocyte-mediated antiviral immunity through dendritic cell maturation

Two distinct chimeric potexviruses share antigenic cross-presentation properties of MHC class I epitopes

Expression of multiple proteins using full-length and deleted versions of Cowpea mosaic virus RNA-2

Cowpea mosaic virus-based systems for the expression of antigens and antibodies in plants

A virus-based nanoplasmonic structure as a surface-enhanced Raman biosensor

Structural insights into magnetic clusters grown inside virus capsids

High immunogenicity of plant-produced candidate influenza vaccine based on the M2e peptide fused to flagellin

Recent advances of cowpea mosaic virus-based particle technology

Fine-tuning levels of heterologous gene expression in plants by orthogonal variation of the untranslated regions of a nonreplicating transient expression system

Rapid transient production in plants by replicating and non-replicating vectors yields high quality functional anti-HIV antibody

Expression of active recombinant human gastric lipase in Nicotiana benthamiana using the CPMV-HT transient expression system

A method for rapid production of heteromultimeric protein complexes in plants: Assembly of protective bluetongue virus-like particles

Engineering recombinant virus-like nanoparticles from plants for cellular delivery

Endothelial targeting of cowpea mosaic virus (CPMV) via surface vimentin

Cowpea mosaic virus nanoparticles target surface vimentin on cancer cells

Infusion of imaging and therapeutic molecules into the plant virus-based carrier cowpea mosaic virus: Cargo-loading and delivery

In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer

The rat ErbB2 tyrosine kinase receptor produced in plants is immunogenic in mice and confers protective immunity against ErbB2+ mammary cancer

Efficient transient expression of recombinant proteins in plants by the novel pEff vector based on the genome of potato virus X. Front

Nanoparticle encapsidation of Flock house virus by auto assembly of Tobacco mosaic virus coat protein

DNA virus vectors for vaccine production in plants: Spotlight on geminiviruses

A DNA replicon system for rapid high-level production of virus-like particles in plants

High level protein expression in plants through the use of a novel autonomously replicating geminivirus shuttle vector

Production of Human papillomavirus pseudovirions in plants and their use in pseudovirion-based neutralisation assays in mammalian cells

Expression of a recombinant chimeric protein of hepatitis A virus VP1-Fc using a replicating vector based on Beet curly top virus in tobacco leaves and its immunogenicity in mice

In plant activation: An inducible, hyperexpression platform for recombinant protein production in plants

Design and construction of an in-plant activation cassette for transgene expression and recombinant protein production in plants

Targeting cancer with "smart bombs": equipping plant virus nanoparticles for a 'seek and destroy' mission

Plant virus particles carrying tumour antigen activate TLR7 and Induce high levels of protective antibody

Efficient generation of cowpea mosaic virus empty virus-like particles by the proteolytic processing of precursors in insect cells and plants

Interaction of Cowpea mosaic virus (CPMV) nanoparticles with antigen presenting cells in vitro and in vivo